PROMIS NEUROSCIENCES APPOINTS INTERNATIONALLY RECOGNIZED RESEARCHER IN ALZHEIMER’S DISEASE IN DOWN SYNDROME DR. ANDRE STRYDOM TO ITS SCIENTIFIC ADVISORY BOARD

TORONTO, Ontario and CAMBRIDGE, Mass.—August 27, 2019—ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, has added Dr. Andre Strydom to its scientific advisory board (SAB). Dr. Strydom is a world-recognized expert in ageing-related issues in Down syndrome and his research has advanced understanding of Alzheimer’s disease (AD) in Down syndrome patients. His expertise and advocacy will help guide ProMIS development plans relating to treatment of AD in Down syndrome. MORE>>